Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias

Suzanne M Vercauteren; Ali Bashashati; Donghong Wu; Ryan R Brinkman; Connie Eaves; Allen Eaves; Aly Karsan

doi:10.1016/j.leukres.2009.03.019

Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias

Leuk Res. 2009 Dec;33(12):1636-42. doi: 10.1016/j.leukres.2009.03.019. Epub 2009 May 2.

Authors

Suzanne M Vercauteren¹, Ali Bashashati, Donghong Wu, Ryan R Brinkman, Connie Eaves, Allen Eaves, Aly Karsan

Affiliation

¹ Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, Canada.

PMID: 19414193
DOI: 10.1016/j.leukres.2009.03.019

Abstract

We studied the diagnostic role of CFC assays in myelodysplastic syndromes (MDS) using CFC data from bone marrow (BM) and peripheral blood (PB) of 221 MDS patients, 51 patients with non-malignant causes of cytopenia and/or dysplasia and 50 normal controls. A consistent decrease in BM but not PB multi-lineage and erythroid progenitor frequencies was seen in patients with MDS compared to controls (P<0.05). Automated distinction showed a sensitivity of 87+/-6% and a specificity of 71+/-11% in classifying MDS patients. In conclusion, a defect in early hematopoietic progenitor activity, in particular erythroid activity, distinguishes MDS from non-MDS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Lineage*
Cluster Analysis
Diagnosis, Differential
Hematologic Diseases / diagnosis*
Humans
Karyotyping
Myelodysplastic Syndromes / blood
Myelodysplastic Syndromes / diagnosis*
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology
Sensitivity and Specificity